Obese patients
Conditions
Interventions
Reimazolam group:Anesthesia induction: Reimazolam besylate was infused at an infusion rate of 12 mg/kg/h, and the patients level of consciousness was assessed using the modified observer alertness/sed
Propofol group:Anesthesia induction: Slow bolus injection of propofol 2-2.5mg/kg. Anesthesia maintenance: Propofol is administered at a rate of 4-12mg/kg/h and adjusted appropriately according to the
Sponsors
The First Affiliated Hospital of Zhengzhou University
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1. Patients undergoing elective general anesthesia surgery; 2. Age 18-65 years old, gender is not limited; 3. American Society of Anesthesiologists ASAI.-III. 4. Body mass index BMI >=30 kg/m^2; 5. Non-emergency surgery with an estimated operation time of less than 5 h; 6. Patients voluntarily participate in the trial and sign the informed consent form.
Exclusion criteria
Exclusion criteria: 1. Subject unequivocally refuses to participate in this study; 2. Those who have contraindications to deep sedation/general anesthesia or have a history of sedation/anesthesia accidents in the past; 3. Those who are known to be allergic to eggs, soy products, opioids and their antidotes, propofol, remimazolam besylate, etc.; Propofol, benzodiazepines, opioids and contraindications to their antidotes; 4. History of having severe liver, kidney, digestive system, hematologic, neuromuscular system, or metabolic system, which in the judgment of the investigator may increase the risk of sedation/anesthesia, and is not suitable for participation in the study; 5. Long-term use of analgesics, psychotropic drugs (including opioids, NSAIDs, sedatives, antidepressants), alcohol abuse for chronic pain, and suspected abuse of narcotic analgesics or sedatives; 6. The following respiratory management risks were identified during the screening period: (1) History of asthma, stridor; (2) Sleep apnea syndrome; (3) Have a history or family history of malignant hyperthermia; (4) Those who have failed tracheal intubation; (5) History of acute inflammation of the respiratory tract within 2 weeks with no cure; (6) suffer from esophageal reflux; (7) Difficulty in airway or difficulty in endotracheal intubation as judged by the investigator at screening (modified Marhalanobis score grade IV.); 7. Those who have participated in any drug clinical trials within 1 month prior to screening; Patients with opioid and sedative/anesthetic use 3 days prior to consultation; 8. Pregnant or parturient; 9. ECG Tips: Heart rate<50 beats/min; 10. Have taken monoamine oxidase inhibitory drugs or antidepressants within 15 days; 11. Subjects who, in the opinion of the investigator, have any other factors that are not suitable for participating in this clinical study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Incidence of adverse events during induction; | — |
Secondary
| Measure | Time frame |
|---|---|
| Extubation time;loss of consciousness time;Hemodynamics; | — |
Countries
China
Contacts
Public ContactZhongyu Wang
The First Affiliated Hospital of Zhengzhou University
Outcome results
None listed